Navigation Links
Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Date:12/18/2007

HOPKINTON, Mass., Dec. 18 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc., (Nasdaq: ALSE), announced today that it has enrolled the first subject in the initial stage of the ALTROPANE(R) Parkinson's or Essential Tremor - 2 (POET-2) Phase III clinical trial program. This subject was enrolled at the University of Alabama, Birmingham trial site under the direction of Principal Investigator Dr. Ray L. Watts, MD, Professor and Chairman of the Department of Neurology.

ALTROPANE is a diagnostic molecular imaging agent being developed to aid in the differentiation of Parkinsonian Syndromes from non-Parkinsonian tremor. An estimated 10 million Americans are presently living with tremor. Currently, tremor disorders are diagnosed by subjective clinical evaluation which, according to the Canadian Journal of Neuroscience, is associated with an error rate among general neurologists of 25% to 35%.

Dr. Mark Hurtt, the Company's Chief Medical Officer, commented, "The enrollment of the first subject in the POET-2 Phase lll program is an important milestone for Alseres as we continue the process of moving ALTROPANE toward regulatory approval. We believe that ALTROPANE has the potential to help doctors more accurately diagnose tremor to minimize the side-effects of unnecessary treatments. ALTROPANE may also provide diagnostic support to monitor disease progression and the effects of emerging therapeutics."

Dr. Ray L. Watts, M.D. of University of Alabama -- Birmingham, Movement Disorder Specialist, stated "ALTROPANE may prove to be a valuable tool in assisting neurologists with their clinical diagnosis of Parkinsonian Syndromes, especially in the early stages."

About the "Parkinson's or Essential Tremor" (POET-2) Trial Prog
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Seventy-one percent of Americans believe the ... a serious public health and safety issue in ... survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication abuse problem ... this very serious health situation facing our country," Rex ...
(Date:8/21/2014)...  Henry Schein, Inc. (NASDAQ: HSIC ), the ... office-based dental, animal health and medical practitioners, announced today that ... , September 4, 2014 – Baird 2014 Healthcare ... p.m. ET , September 8, 2014 – ... , NY at 1:25 p.m. ET Henry ...
(Date:8/21/2014)... 2014 CVS Caremark Corporation (NYSE: CVS ... and consideration payable in connection with its previously announced cash ... for (1) any and all of its 6.250% Senior Notes ... to a maximum amount of its 6.125% Senior Notes due ... due 2017 (collectively, the "Maximum Tender Offer Notes" and together ...
Breaking Medicine Technology:Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3Henry Schein To Present At Two Investor Conferences In September 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
... 2011 ConvaTec Healthcare, a world-leading developer, manufacturer and ... care, today announced that, following a review of current ... refinancing of its senior secured term loans originally entered ... ConvaTecConvaTec is a leading developer and marketer of innovative ...
... March 17, 2011 Giant Eagle®, the region,s leading ... Association,s (ADA) prestigious Chairman,s Citation Award. Giant ... which recognizes the outstanding accomplishments of individuals, corporations, institutions ... and have had a positive impact in advancing the ...
Cached Medicine Technology:ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans 2ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans 3Giant Eagle® Receives American Diabetes Association Chairman's Citation Award 2Giant Eagle® Receives American Diabetes Association Chairman's Citation Award 3
(Date:8/22/2014)... (PRWEB) August 22, 2014 Key West ... care experts revealed their much anticipated study results of ... skin today and released an accompanying infographic on their ... in can have a major impact on the skin ... wrinkles and more. , When asked how they determined ...
(Date:8/22/2014)... (ESMO), the leading pan-European organisation representing medical oncology ... individuals receiving the Society,s esteemed annual awards. The ... Joensuu and Peter Boyle on the occasion of ... , Carsten Bokemeyer will receive the ESMO Award ... cancer discovery into real benefit at patient level. ...
(Date:8/22/2014)... provides insight on how the brain processes external input ... and sides of the body, in order to select ... in the journal Neuron , show that the ... of sensory information, with specialised functional roles for the ... input structure in the basal ganglia, and is typically ...
(Date:8/22/2014)... the leading pan-European organisation representing medical oncology professionals, ... receiving the Society,s esteemed annual awards. The awards ... and Peter Boyle on the occasion of the ... Carsten Bokemeyer will receive the ESMO Award for ... discovery into real benefit at patient level. 1 ...
(Date:8/22/2014)... News) -- The air in American cities is getting ... Thursday. Significant progress has been made in reducing ... decades, the agency said in a news release. ... reduction in mercury from human sources such as coal-fired ... 84 percent fall in lead, which harms brain development ...
Breaking Medicine News(10 mins):Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:The striatum acts as hub for multisensory integration 2Health News:ESMO honours outstanding oncology professionals 2Health News:ESMO honours outstanding oncology professionals 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2
... awe, not to mention a little fear or suspicion; it is ... hope to enter. Such an // approach can be dangerous if ... ,If the public is to have a say in developing guidelines ... clear sense of what science can and cannot be expected to ...
... people in the world after South Africa and now threats// ... to a World Economic Survey. ,The surveys message ... business due to AIDS in the next five years.", ... report some impact of the AIDS virus on ...
... checking the profits and safety of the drugs the ... monitor that only branded and quality medicines are sold ... Pharmaceutical Price Regulation Scheme [PPRS] is a voluntary organization ... and quality of the drugs every 5 years. It ...
... a disaster-planning guide to help the people who live ... hurricanes, tidal waves and cyclones. ,No matter where ... some sort of natural disaster such as a blizzard, ... are also possible. Both natural disasters and terrorist attacks ...
... increasing malfunction of heart devices, which they say were ... ,The Food and Drug Administration (FDA) released // ... manufacturers recently, which found that 4,225 defibrillators had failed ... in the previous 10 years, reports online edition of ...
... repair the damages in the heart from the use of stem ... to repair heart damage in sheep, reporting their results // in ... failure is a major cause of death in developed countries, occurring ... Before now, embryonic stem cells had been used to limit the ...
Cached Medicine News:Health News:Scientists Awarded Appropriately For Contribution Towards Medical Research 2Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Disaster Planning Guide From Harvard Health Publications 2Health News:Scientists Concerned Over Increasing Malfunction Of Heart Devices 2
... Powerful refrigerated floor-standing centrifuge. Mobile ... rotors, large choice of accessories, analog ... detection & shutdown (JOUAN patented pendulum ... current and temperature limitation, rugged motor, ...
... high and low speed refrigerated centrifuge. ... AUTO-LOCK JOUAN patented system, comprehensive control ... Lifetime reproducibility, individual password protection of ... rates (100 run profiles), powerful refrigeration ...
GP8RF is a powerful 3-liter ventilated centrifuge which is flexible, easy to use and fit on, beside or below the lab bench. Performs separations 50-100% faster than the rest, powerful, accommodating ...
... refrigerated. The Centra-CL3 is ideal for ... (meeting US OSHA Bloodborne Pathogen Final ... Falcon/Corning conicals, large volume concentrations up ... pelleting and many other industrial, research ...
Medicine Products: